Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

04. April 2022 12:00 ET | Quelle: OSE Immunotherapeutics

OSE Immunotherapeutics Invited to Present Preclinical Data on its PD-1/IL-7 Bifunctional Program BiCKI®-IL-7 Cancer Immunotherapy

At American Association for Cancer Research Annual (AACR) Meeting 2022New Orleans, April 8 – 13 NANTES, France, April 04, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173;...
30. März 2022 12:00 ET | Quelle: OSE Immunotherapeutics

OSE Immunotherapeutics Reports 2021 Financial Results: Major Progress on its Clinical Programs and a Solid Cash Position to Support its Activities

Shared positive final Phase 3 results for Tedopi® in non-small cell lung cancer (NSCLC) patients in secondary resistance after failure with second-line checkpoint inhibitor treatment.Received an €8...
21. März 2022 13:00 ET | Quelle: OSE Immunotherapeutics

OSE Immunotherapeutics Receives First Notice of Allowance for a US Patent Covering Anti-PD1 Monoclonal Antibody OSE-279 And its Use in Cancer Treatment

Issued by the United States Patent and Trademark Office A New Protection Covering OSE-279 Until 2039 NANTES, France, March 21, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN:...
16. März 2022 13:00 ET | Quelle: OSE Immunotherapeutics

OSE Immunotherapeutics Provides Positive Long Term Memory Responses with CoVepiT, its T Lymphocyte Multi-Target Anti-COVID Vaccine

Positive long term immunological results at 6 months in healthy volunteers with strong T cell memory responses against virus proteins.CoVepiT, based on 13 peptides, elicits durable T-cell immunity...
09. März 2022 01:30 ET | Quelle: OSE Immunotherapeutics

Boehringer Ingelheim and OSE Immunotherapeutics To Present Biomarker Analyses from the Phase 1 Clinical Trial with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors

At American Association for Cancer Research Annual Meeting 2022New Orleans, April 8 – 13 NANTES, France, March 09, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE),...
18. Februar 2022 12:00 ET | Quelle: OSE Immunotherapeutics

OSE Immunotherapeutics Announces Appointment of Alexandre Lebeaut as an Independent Member of the Board of Directors

NANTES, France, Feb. 18, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced the appointment by cooptation of Alexandre Lebeaut as an independent...
17. Februar 2022 12:00 ET | Quelle: OSE Immunotherapeutics

OSE Immunotherapeutics is Pleased to Announce that Veloxis Pharmaceuticals, Inc., its Partner in Transplantation, has Obtained FDA Fast-Track Designation for CD28 Antagonist VEL-101/FR104

NANTES, France, Feb. 17, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that Veloxis Pharmaceuticals, Inc., an Asahi Kasei company, has obtained...
01. Februar 2022 01:30 ET | Quelle: OSE Immunotherapeutics

Transfer of OSE Immunotherapeutics’ Shares from Compartment C to Compartment B of Euronext Paris from January 31, 2022

NANTES, France, Feb. 01, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that its shares have been transferred from compartment C to compartment B...
31. Januar 2022 12:00 ET | Quelle: OSE Immunotherapeutics

OSE Immunotherapeutics Announces Acceptance of the US Investigational New Drug (IND) Application Obtained by Veloxis Pharmaceuticals, Inc., its Partner in Transplantation, for CD28 Antagonist VEL-101/FR104

Based on the global license agreement signed in April 2021, this first milestone triggers a €5 million payment from Veloxis Pharmaceuticals, Inc. to OSE Immunotherapeutics. NANTES, France, Jan. ...
25. Januar 2022 12:30 ET | Quelle: OSE Immunotherapeutics

OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use of Tedopi® after Failure with PD-1 or PD-L1 Immune Checkpoint Inhibitor Treatment in HLA-A2 Positive Cancer Patients

Issued by the Japanese Patent OfficeA New Protection Covering Tedopi® Until 2037 NANTES, France, Jan. 25, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)...

Vorherige Seite

Nächste Seite